An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects

被引：0
|
作者：
Desmond Padhi
Craig B. Langman
Sahar Fathallah-Shaykh
Bradley A. Warady
Isidro B. Salusky
Edward Lee
Christine Wang
Edward Posvar
机构：
[1] Amgen Inc.,Early Development
[2] Northwestern University,Feinberg School of Medicine, Children’s Memorial Hospital
[3] University of Alabama at Birmingham,Division of Pediatric Nephrology
[4] University of Missouri–Kansas City School of Medicine,Children’s Mercy Hospitals and Clinics
[5] David Geffen School of Medicine at UCLA,Division of Pediatric Nephrology, Department of Pediatrics
[6] Amgen Inc.,Metabolic Disorders
来源：
Pediatric Nephrology | 2012年 / 27卷
关键词：
Hyperparathyroidism; CKD–MBD; Hemodialysis; End-stage renal disease; Pharmacokinetics; Pharmacodynamics; Secondary;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1953 / 1959
页数：6
相关论文
共 50 条
  • [41] Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
    Aaronson, Scott T.
    van der Vaart, Andrew
    Miller, Tammy
    Lapratt, Jeffrey
    Swartz, Kimberly
    Shoultz, Audrey
    Lauterbach, Margo
    Suppes, Trisha
    Sackeim, Harold A.
    AMERICAN JOURNAL OF PSYCHIATRY, 2025, 182 (01): : 104 - 113
  • [42] Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
    Yalcin Solak
    Seyyid Bilal Acikgoz
    Mehmet Yildirim
    Clinical Drug Investigation, 2015, 35 : 149 - 149
  • [43] Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open-Label, Single-Dose, Parallel-Group Study
    Bhardwaj, Rajinder
    Ivans, Andrea
    Stringfellow, Joseph
    Morris, Beth
    Coric, Vladimir
    Croop, Robert
    Bertz, Richard
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (08): : 790 - 800
  • [44] Rimegepant 75 mg in Subjects with Hepatic Impairment: Results of a Phase 1, Open-label, Single-dose, Parallel-group Study
    Croop, R.
    Stringfellow, J.
    Ivans, A.
    Coric, V
    HEADACHE, 2019, 59 : 178 - 178
  • [45] Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment
    Ivans, Andrea
    Stringfellow, Joseph
    Coric, Vladimir
    Croop, Robert
    NEUROLOGY, 2020, 94 (15)
  • [46] Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment
    Croop, Robert
    Stringfellow, Joseph
    Ivans, Andrea
    Coric, Vladimir
    CEPHALALGIA, 2019, 39 : 200 - 200
  • [47] Open-label, single-dose, phase I study evaluating the mass balance and pharmacolkinetics (PKs) of sunitinib (SU) in healthy male subjects
    Sherman, L.
    Peng, G.
    Patyna, S.
    Pool, W.
    Smeraglia, J.
    Bello, C. L.
    Garrett, M.
    Klamerus, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 116 - 116
  • [48] Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
    Solak, Yalcin
    Acikgoz, Seyyid Bilal
    Yildirim, Mehmet
    CLINICAL DRUG INVESTIGATION, 2015, 35 (02) : 149 - 149
  • [49] Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
    Wason, Suman
    Mount, David
    Faulkner, Robert
    CLINICAL DRUG INVESTIGATION, 2014, 34 (12) : 845 - 855
  • [50] A MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF SOLIFENACIN SUCCINATE SUSPENSION IN PEDIATRIC SUBJECTS FROM 5 TO LESS THAN 18 YEARS OF AGE WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO).
    Bosman, B.
    Tannenbaum, S.
    Winklewski, P.
    Den Adel, M.
    Newgreen, D.
    Baka-Ostrowska, M.
    NEUROUROLOGY AND URODYNAMICS, 2013, 32 (06) : 932 - 933
12345